<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809767</url>
  </required_header>
  <id_info>
    <org_study_id>CS1003-102</org_study_id>
    <nct_id>NCT03809767</nct_id>
  </id_info>
  <brief_title>A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas</brief_title>
  <official_title>A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to
      evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1003 in
      subjects with advanced solid tumors or lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>from the day of first dose to 90 days after last dose of CS1003</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>CS1003 monoclonal antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1003 monoclonal antibody</intervention_name>
    <description>CS1003 will be administered intravenously every 3 weeks.</description>
    <arm_group_label>CS1003 monoclonal antibody</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to sign the informed consent.

          2. Subjects must have histologically or cytologically confirmed advanced or metastatic
             solid tumor or unresectable lymphoma and have progressed, are intolerant to, refuse to
             accept or do not have access to standard therapy.

          3. ECOG performance status of 0 or 1.

          4. Subjects with evaluable but non-measurable lesion are eligible for Phase Ia. Subjects
             must have at least one measurable lesion per RECIST Version 1.1 to be eligible for
             Phase Ib.

          5. Archived tumor tissue samples need to be collected, or subjects consent to undergo
             pre-treatment biopsy if archived sample is not available.

          6. Life expectancy â‰¥ 3 months.

          7. Subject must have adequate organ function.

          8. Use of effective contraception (males and females).

        Exclusion Criteria:

          1. Subjects with known symptomatic or untreated brain metastasis or other CNS metastasis.

          2. Subjects with active autoimmune diseases or history of autoimmune diseases.

          3. Subjects who have to receive glucocorticoids (prednisone at &gt; 10 mg/day or equivalent)
             or other immunosuppression within 14 days prior to the first dose of CS1003.

          4. Subjects with other malignant tumor(s) in the past 2 years are not eligible for Phase
             Ib

          5. Subjects who have received any immune checkpoint treatment, including PD-1, PD-L1,
             etc.

          6. History of HIV infection.

          7. Subjects with active Hepatitis B and C infection requiring therapy.

          8. Subjects with active infection of tuberculosis.

          9. History of organ transplantation.

         10. Unresolved toxicities from prior anti-cancer therapy.

         11. History of uncontrolled allergic asthma and serious hypersensitive reaction to
             monoclonal antibodies.

         12. Subjects with major cardiovascular diseases.

         13. History of alcoholism or drugs abuse.

         14. Any condition that, in the opinion of the investigator or sponsor, would jeopardize
             compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wendie Yuan</last_name>
    <phone>+86 21 61097678</phone>
    <email>cstonera@cstonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

